Strategic Partnership AmeriPath is a division of Quest Diagnostics and recently partnered with Envision Sciences to expand biomarker-based cancer diagnostics, presenting an opportunity to cross-sell integrated pathology and molecular testing services to oncology and urology/radiology accounts.

Market Leadership Positioned as a leading cancer diagnostics provider with extensive outpatient and hospital-based labs, offering a broad suite of dermatopathology, anatomic pathology, and molecular testing that can be bundled with Quest Diagnostics services for larger health systems.

Technology Enablement Utilize a modern tech stack including cloud, cloud security and monitoring (Azure, OneTrust, Dynatrace, Cloudflare) to emphasize data security, compliance, and scalable test ordering and reporting to enterprise customers seeking robust IT integration.

Growth and Funding Signals Revenue range indicates a midsize to large-cap opportunity with potential for upsell in high-margin molecular diagnostics, prostate cancer biomarkers, and specialized pathology services to expand average contract value with existing Quest Diagnostics relationships.

Expansion Opportunities Leverage ongoing collaborations and the extensive physician and laboratory network to target health systems and ASC networks that demand integrated diagnostic workflows, leveraging AmeriPath’s subspecialty capabilities to win top-tier cancer care contracts.